The organic vs inorganic growth story at Grace Therapeutics GRCE Grace Therapeutics 51 EPS beat tops loss views Gilead Sciences GILD Q1 2026 Earnings Analysis Revenue Beats Forecast Amid Mixed Product Performance INOD Innodata tops Q4 2025 EPS estimates by 163 percent shares rise 191 percent in todays session MLACR Mountain quarterly filing shows no revenue as acquisition pipeline remains central focus for SPAC investors